Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Revenue (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Revenue for 16 consecutive years, with $59.7 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 39.37% to $59.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $268.1 million through Dec 2025, up 60.4% year-over-year, with the annual reading at $268.1 million for FY2025, 60.4% up from the prior year.
  • Revenue hit $59.7 million in Q4 2025 for Ligand Pharmaceuticals, down from $115.5 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $115.5 million in Q3 2025 to a low of $26.4 million in Q2 2023.
  • Historically, Revenue has averaged $50.2 million across 5 years, with a median of $47.1 million in 2021.
  • Biggest five-year swings in Revenue: plummeted 47.4% in 2023 and later skyrocketed 122.85% in 2025.
  • Year by year, Revenue stood at $56.4 million in 2021, then decreased by 10.68% to $50.4 million in 2022, then crashed by 44.22% to $28.1 million in 2023, then soared by 52.35% to $42.8 million in 2024, then soared by 39.37% to $59.7 million in 2025.
  • Business Quant data shows Revenue for LGNDZ at $59.7 million in Q4 2025, $115.5 million in Q3 2025, and $47.6 million in Q2 2025.